A Phase 2 Study Comparing Rituximab and Mosunetuzumab Immunotherapy in People with Nodular Lymphocyte-Predominant Hodgkin Lymphoma


Full Title

NORM: Nodular Lymphocyte-Predominant Hodgkin Lymphoma Patients Treated in a Randomized Phase 2 Trial with Either Rituximab or Mosunetuzumab (NCI 10590) (CIRB)


Researchers are comparing mosunetuzumab to the usual treatment (rituximab) for nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). They want to see if one drug is more effective than the other to shrink the cancer with a long-lasting response.

Rituximab and mosunetuzumab are monoclonal antibodies. They bind to a protein called CD20. This protein is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells.

If you join this study, you will be randomly assigned to get either rituximab or mosunetuzumab. Rituxumab is given intravenously (by vein) or as an injection under the skin. Mosunetuzumab is an injection given under the skin.

Who Can Join

To join this study, there are a few conditions. You must:

  • Have NLPHL which is either untreated or keeps growing even after treatment.
  • Not have had prior treatment with rituximab.
  • Have recovered from the serious side effects of previous therapies before getting the study treatment.
  • Be able to walk and do routine activities for more than half the time you are awake.
  • Be age 18 or older.


For more information and to see if you can join this study, please call Dr. Raphael Steiner’s office at 646-608-4330.




Phase II (phase 2)

Disease Status

Newly Diagnosed & Relapsed/Refractory



ClinicalTrials.gov ID